ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmstandard, Russia’s largest pharmaceutical firm, is set to acquire Bever Pharmaceutical, a Singapore-based manufacturer of active pharmaceutical ingredients, for $590 million from Bristley Enterprises. Bristley is owned by Pharmstandard non-executive-board member Alexander Shuster. Pharmstandard says the acquisition will provide it with a long-term, fixed-cost supply of key APIs for two of its leading over-the-counter products and increase profits for the firm’s OTC business, which it plans to spin off into a separate company.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter